Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotech company focused on neuropsychiatric disorder treatments, has announced its participation in the upcoming H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotech company focused on neuropsychiatric disorder treatments, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, Dr. Spyros Papapetropoulos, will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET, accessible through both the conference platform and Neuphoria's investor relations website.
Details
News Market Reaction – NEUP
On Aug 29, the first trading day after this news, NEUP closed 7.21% below the previous close.
Data tracked by StockTitan Argus for the Aug 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
The presentation will be available on demand here starting on Friday, September 5 at 7:00 a.m. ET. The webcast will also be available on the “Events” page in the investors section of Neuphoria’s website.
About Neuphoria Therapeutics Inc.
Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC-210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed” treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC-210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Spyridon (Spyros) Papapetropoulos info@neuphoriatx.com | IR & PR Argot Partners neuphoria@argotpartners.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.